Hylomorph AG - Company Research Report

1. Company Overview

Name

Hylomorph AG

Mission

Hylomorph is committed to pioneering innovation in preventive medicine with a focus on improving and saving lives through medical devices and drug-device combinations that prevent implant complications and ensure patient well-being post-surgery.

Foundation

Founded: 2015

By: Simone Bottan (CEO & Co-founder), Aldo Ferrari (CSO & Co-founder), Francesco Robotti (COO & Co-founder)

Key People

Simone Bottan: CEO & Co-founder

Aldo Ferrari: CSO & Co-founder

Francesco Robotti: COO & Co-founder

Sebastian Cavalli: CRQO

Georgios Stefopoulos: Head of Product Development

Headquarters

Location: Technopark Zurich, Zurich, Switzerland

Number of Employees

Size: 11-50 employees

Revenue

No information is available.

Recognition

Hylomorph is renowned for engineering innovative medical devices and drug-device combinations aimed at preventing implant complications.

2. Products

Product Offerings

Vesta: The primary product offered by Hylomorph, Vesta is a next-generation bioresorbable, antibiotic-eluting envelope for Cardiac Implantable Electronic Devices (CIEDs) including Pacemakers, Implantable Cardioverter Defibrillators (ICDs), and Cardiac Resynchronization Therapies (CRTs).

Product Description

Vesta: Designed for electrophysiologists and cardiologists, Vesta provides a stable holding and sustained, localized antibiotic elution to reduce infection risks associated with CIEDs.

Key Features of Vesta

Antibiotic Eluting: Provides controlled release of antibiotics to prevent infections.

Bioresorbable: Constructed from biocompatible materials that dissolve in the body after the intended function is fulfilled.

Human-Centered Design: Focused on ease of use in surgical settings and comfort for the patient with a 1-minute preparation time.

Customizable: Offers precise tuning of active compound release to tailor the dosage and dynamics to clinical requirements.

3. Recent Developments

Recent Developments

Product Innovations: Vesta has recently been highlighted for its innovative contributions to infection prevention in medical implants.

Funding Milestone: Securement of a Series B funding round amounting to $5.1M as of October 5, 2023, with EFI Lake Geneva Ventures and five other investors.

New Product Launches

No information is available.

New Features Added to Existing Products

No specific new features mentioned beyond those currently integrated into the Vesta envelope technology.

New Partnerships

No specific partnerships mentioned; however, there is a strong emphasis on collaboration with healthcare professionals for product development.

This report consolidates the mentioned information available on Hylomorph AG. The company demonstrates a significant focus on advancing healthcare through innovative solutions that address medical needs, specifically infection prevention associated with implantable medical devices.